Phase III Trial of Single-Agent Pemetrexed (Alimta) Versus the Combination of Carboplatin and Pemetrexed in Patients With Advanced Non-small-cell Lung Cancer and Performance Status of 2

Trial Profile

Phase III Trial of Single-Agent Pemetrexed (Alimta) Versus the Combination of Carboplatin and Pemetrexed in Patients With Advanced Non-small-cell Lung Cancer and Performance Status of 2

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2013

At a glance

  • Drugs Pemetrexed (Primary) ; Carboplatin
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jun 2013 Results published in the Journal of Clinical Oncology.
    • 01 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top